FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.	C. 20549
----------------	----------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWN
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Bellinger Andrew					2. Issuer Name and Ticker or Trading Symbol Verve Therapeutics, Inc. [VERV]								neck all appli Direct	cable) `		Ssuer Dwner (specify	
	RVE THER	irst) APEUTICS, INO Y SQUARE, SU			3. Date of Earliest Transaction (Month/Day/Year) 07/20/2022								^ below		below & CMO		
(Street) CAMBR (City)	LIDGE M	[A	02139 (Zip)	4	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. l	e) X Form	′			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Da			2. Transacti Date (Month/Day	th/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		Execution Date, if any		, Transaction Dis Code (Instr. 5)		I. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		Benefic Owned	es Following (I)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	(A) o (D)	r Price	Transac	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
Common Stock 07/20,				07/20/20	022			М		20,00	0 A	\$1.3	9 26	,629	D		
Common Stock 07/20.			07/20/20)/2022		S ⁽¹⁾		20,000 D		\$34.	9 6,629		D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Yea	Code	Transaction Code (Instr.		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership t (Instr. 4)	
				Code	e V	(A)	(D)	Date Exercisab		expiration Pate	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$1.39	07/20/2022		М			20,000	(2)	0	6/24/2029	Common Stock	20,000	\$0.00	1,599	D		

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2022.
- $2. \ The \ option \ was \ granted \ on \ June \ 25, 2019 \ for \ 21,599 \ shares. \ The \ shares \ underlying \ the \ option \ vested \ on \ May \ 1, 2020.$

Remarks:

/s/ Andrew Ashe, as Attorneyin-Fact for Andrew Bellinger ** Signature of Reporting Person

Date

07/22/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.